Opendata, web and dolomites

TWO-BIRDS SIGNED

A feasibility study for SYT-510, a first-in-class drug to treat neuropsychiatric disorders through restoring overall balance in brain chemistry

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TWO-BIRDS project word cloud

Explore the words cloud of the TWO-BIRDS project. It provides you a very rough idea of what is the project "TWO-BIRDS" about.

action    million    co    regulate    clinician    circuit    patient    traumatic    ineffective    chemistry    coerced    psychological    anti    preclinical    disorders    mechanism    70    demonstrated    population    attractive    dependency    small    reuptake    safety    symptoms    patients    safe    victims    combined    family    commercialize    relive    birds    partnering    trauma    start    manner    molecule    ptsd    people    disrepair    investor    selective    flashbacks    pharmacokinetic    business    15    syt    restoring    circuits    510    thereby    severe    feasibility    synendos    termed    master    plan    eventual    triggers    treatment    unforgiving    deals    limiting    clinical    brain    chemistries    sales    hold    risk    nightmares    regulatory    unfortunately    sustainable    intrusive    stage    self    compound    paradigm    profile    consolidate    balance    first    companies    function    relief    modulate    never    thoughts    downstream    disorder    neuroregulator    anxiety    pharma    experiences    restore    endocannabinoid    market    drugs    stress    endocx    seris    neural    pharmaceutical    ready    dysregulated    understand    post    establishing    final    inhibitors    drug    provoke    cognitive   

Project "TWO-BIRDS" data sheet

The following table provides information about the project.

Coordinator
SYNENDOS THERAPEUTICS AG 

Organization address
address: SWISS INNOVATION PARK, GEWERBESTRASSE 24
city: ALLSCHWIL
postcode: 4123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNENDOS THERAPEUTICS AG CH (ALLSCHWIL) coordinator 50˙000.00

Map

 Project objective

PTSD affects over 15 million people in Europe. So far, 70% never find relief. New drugs that restore the endocannabinoid (endoCx) neural circuit hold potential to change this paradigm.

Post-traumatic stress disorder, known as PTSD, is one of the most unforgiving psychological disorders. As victims of trauma, PTSD patients are coerced by their dysregulated brain chemistries to relive their traumatic experiences, where specific triggers provoke symptoms such as flashbacks, intrusive thoughts, nightmares and severe anxiety. Unfortunately, current drugs address only specific downstream neural circuits and are highly ineffective. The endoCx is highly dysregulated in PTSD, and as a 'master neuroregulator', drugs that restore its function in a safe and sustainable manner have strong potential to be the first effective treatment for PTSD.

Synendos is a pharmaceutical start-up who have identified a new family of drugs that modulate the endoCx via a new mechanism-of-action. Termed SERIs, or, ‘selective endocannabinoid reuptake inhibitors’, these small molecule drugs regulate the endoCx system in a self-limiting manner, thereby restoring balance to brain chemistry without risk of drug dependency or cognitive disrepair. Our lead compound SYT-510 is at the stage of preclinical development, where it has demonstrated effective anti-anxiety activity, favourable pharmacokinetic characteristics and a strong safety profile.

We aim to commercialize SYT-510 through establishing partnering deals with pharma companies for its co-development and eventual sales. With a patient population of over 30 million (in EU/US combined), PTSD is an attractive market for drug development.

TWO-BIRDS project: The main aims of this feasibility study are to 1) work to further understand clinician and patient needs, 2) define a detailed plan for final preclinical, clinical and regulatory activities and 3) consolidate new information into an investor-ready business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TWO-BIRDS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TWO-BIRDS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

FriendlyKnife (2019)

How to get rid of plastic cutlery? Biodegradable products made out of beer waste

Read More